Skip to main content
Medical information Clinical review pending

Genetic Testing

MAMLD1 Gene Hypospadias Type 2 Xlinked Genetic Test

This genetic test analyzes the MAMLD1 gene to identify mutations associated with hypospadias, a congenital condition affecting male genitalia. It helps understand genetic risks and informs family planning.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. A clinical history and genetic counseling session are recommended before testing.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the MAMLD1 Gene Hypospadias Type 2 Xlinked Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a diagnosis of hypospadias.
  • ✓Families with a history of hypospadias.
  • ✓Individuals seeking to understand genetic risk factors for hypospadias.
  • ✓Family planning considerations related to hypospadias.
  • ✓Assisting in the diagnosis of related reproductive disorders.
02

In plain language

What this test helps you understand

Identifies genetic mutations in the MAMLD1 gene associated with hypospadias. Provides information for genetic counseling, family planning, and potential management strategies.
The MAMLD1 Gene Hypospadias Type 2 Xlinked NGS Genetic DNA Test is a specialized genetic analysis focused on the MAMLD1 gene. This gene is linked to hypospadias, a condition present at birth where the opening of the urethra is on the underside of the penis instead of at the tip. Understanding genetic factors related to hypospadias is important for families, particularly those with a history of this or similar conditions. This test uses Next Generation Sequencing (NGS) technology to look for specific changes (mutations) in the MAMLD1 gene. Identifying these mutations can provide valuable information for healthcare providers to guide management and potential treatment options. Discussing the results with a genetic counselor or doctor is crucial to understand their meaning for your health and family.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. A clinical history and genetic counseling session are recommended before testing.
SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS) is used to analyze the MAMLD1 gene for sequence variations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the MAMLD1 gene. Hypospadias can have other genetic and non-genetic causes. A negative result does not completely rule out a genetic contribution. The test may not detect all possible mutations within the MAMLD1 gene.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Hypospadias is a birth defect in males where the opening of the urethra is not located at the tip of the penis.
Individuals diagnosed with hypospadias, families with a history of the condition, or those seeking to understand genetic risks related to hypospadias may consider this test.
The test analyzes a sample of your blood or DNA to look for specific changes in the MAMLD1 gene using Next Generation Sequencing (NGS).
Results indicate the presence or absence of specific mutations in the MAMLD1 gene. Discussing the results with a healthcare provider or genetic counselor is essential for understanding their implications.
No specific patient preparation is required, but a consultation with a healthcare provider or genetic counselor before testing is recommended.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp